Epic Sciences, Inc. is a diagnostics company based in San Diego, California, focused on improving cancer management through innovative testing methods. The company specializes in developing highly sensitive tests to identify and characterize circulating tumor cells (CTCs) from minimally invasive blood samples. Its advanced platform can profile single-cell phenotypes and genotypes, assessing various characteristics such as biomarker expression levels and morphologic traits. Epic Sciences also offers the Oncotype DX AR-V7 Nucleus Detect test for patients with metastatic castration-resistant prostate cancer, along with biopharmaceutical solutions. The company collaborates with biotechnology and pharmaceutical partners, major cancer centers, and research institutions, including the National Cancer Institute and the National Institutes of Health, to enhance personalized medicine and provide real-time biopsy material for cancer treatment guidance. Founded in 2008, Epic Sciences is committed to facilitating quick and effective cancer diagnostics.
Gemelli Biotech is a North Carolina-based biotechnology company founded in 2018 that focuses on the human microbiome and diagnostics for irritable bowel syndrome (IBS). The company develops medical devices and diagnostic tools, including blood tests to measure specific antibodies elevated in patients with post-infectious IBS and a breath test system to identify small intestinal bacterial overgrowth. These innovations aim to enhance diagnostic protocols for various IBS types, including diarrhea-predominant and mixed-type. Gemelli Biotech is committed to advancing healthcare by fostering the discovery of new diagnostics and therapeutics for the microbiome in a responsible and socially conscious manner, ultimately striving to improve global health outcomes.
Epic Sciences, Inc. is a diagnostics company based in San Diego, California, focused on improving cancer management through innovative testing methods. The company specializes in developing highly sensitive tests to identify and characterize circulating tumor cells (CTCs) from minimally invasive blood samples. Its advanced platform can profile single-cell phenotypes and genotypes, assessing various characteristics such as biomarker expression levels and morphologic traits. Epic Sciences also offers the Oncotype DX AR-V7 Nucleus Detect test for patients with metastatic castration-resistant prostate cancer, along with biopharmaceutical solutions. The company collaborates with biotechnology and pharmaceutical partners, major cancer centers, and research institutions, including the National Cancer Institute and the National Institutes of Health, to enhance personalized medicine and provide real-time biopsy material for cancer treatment guidance. Founded in 2008, Epic Sciences is committed to facilitating quick and effective cancer diagnostics.
Sera Prognostics, Inc. is a biotechnology company based in Salt Lake City, Utah, founded in 2008. The company specializes in developing diagnostic tests aimed at predicting a woman's individualized risk of premature birth, preeclampsia, and other pregnancy-related complications. By utilizing proprietary biomarkers, Sera Prognostics seeks to address the significant economic and healthcare challenges associated with premature births, impacting infants, families, and society at large. The company has licensed advanced serum proteomics technology and innovative peptides from Brigham Young University and the University of Utah to support its research and development efforts.
Sera Prognostics, Inc. is a biotechnology company based in Salt Lake City, Utah, founded in 2008. The company specializes in developing diagnostic tests aimed at predicting a woman's individualized risk of premature birth, preeclampsia, and other pregnancy-related complications. By utilizing proprietary biomarkers, Sera Prognostics seeks to address the significant economic and healthcare challenges associated with premature births, impacting infants, families, and society at large. The company has licensed advanced serum proteomics technology and innovative peptides from Brigham Young University and the University of Utah to support its research and development efforts.
Epic Sciences, Inc. is a diagnostics company based in San Diego, California, focused on improving cancer management through innovative testing methods. The company specializes in developing highly sensitive tests to identify and characterize circulating tumor cells (CTCs) from minimally invasive blood samples. Its advanced platform can profile single-cell phenotypes and genotypes, assessing various characteristics such as biomarker expression levels and morphologic traits. Epic Sciences also offers the Oncotype DX AR-V7 Nucleus Detect test for patients with metastatic castration-resistant prostate cancer, along with biopharmaceutical solutions. The company collaborates with biotechnology and pharmaceutical partners, major cancer centers, and research institutions, including the National Cancer Institute and the National Institutes of Health, to enhance personalized medicine and provide real-time biopsy material for cancer treatment guidance. Founded in 2008, Epic Sciences is committed to facilitating quick and effective cancer diagnostics.
Private Equity Round in 2018
RX Solutions, LLC is a company based in Boynton Beach, Florida, that specializes in medical prescription assistance services aimed at helping lower-income individuals access fixed and reduced cost prescription drugs. The organization identifies specific Prescription Assistance Programs (PAPs) tailored to the medication needs of consumers, guiding them through the entire process to secure necessary subsidies and medications. RX Solutions offers assistance for various medications, including Trulicity, Victoza, and ProAir, ensuring that clients receive the support they need to afford their prescriptions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.